Drug Interaction Report
3 potential interactions and/or warnings found for the following 2 drugs:
- cobicistat / darunavir
- benzgalantamine
Interactions between your drugs
darunavir benzgalantamine
Applies to: cobicistat / darunavir, benzgalantamine
Consumer information for this interaction is not currently available.
MONITOR: Coadministration with darunavir may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by darunavir.
MANAGEMENT: Caution is advised if darunavir must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever darunavir is added to or withdrawn from therapy.
cobicistat benzgalantamine
Applies to: cobicistat / darunavir, benzgalantamine
Consumer information for this interaction is not currently available.
MONITOR: Coadministration with potent inhibitors of CYP450 2D6 and/or 3A4 may increase the plasma concentrations of galantamine, which is also an active metabolite of benzgalantamine. Up to 75% of galantamine is eliminated via metabolism and in vitro studies have identified CYP450 2D6 and 3A4 as the major isoenzymes involved. The systemic exposure (AUC) of galantamine (4 mg, 8 mg, or 12 mg twice daily) increased by 40%, 45%, and 48%, respectively, when administered to healthy volunteers (n=16) also receiving the strong CYP450 2D6 inhibitor paroxetine. Similarly, the strong CYP450 3A4 inhibitor ketoconazole (200 mg twice daily) increased the AUC of galantamine (4 mg twice daily) by 30% when given concurrently to study subjects (n=16). An increase in the AUC of galantamine can increase the risk of acetylcholinesterase inhibitor-related adverse effects. One potential side effect of galantamine is bradycardia, which may increase the risk of QT prolongation. If the inhibitor being coadministered is also associated with QT prolongation (e.g., adagrasib, ceritinib, fluoxetine, ketoconazole, levoketoconazole, mifepristone), the risk of experiencing this adverse effect may be further increased.
MANAGEMENT: Caution and closer monitoring of the pharmacologic response to galantamine and its prodrug benzgalantamine is advised whenever a potent CYP450 2D6 and/or 3A4 inhibitor is added to or withdrawn from therapy. Some authorities suggest considering a reduction in the galantamine dose for patients on concurrent potent CYP450 2D6 and/or 3A4 inhibitors. Patients should be monitored more closely for acetylcholinesterase inhibitor related adverse effects including vagotonic effects on the heart rate (e.g., bradycardia, which may increase the risk of QT prolongation, and heart block), neurologic side effects (e.g., seizure activity), respiratory distress, bladder outflow obstruction, dizziness or syncope, nausea, vomiting and diarrhea. These effects may be more severe when the coadministered inhibitor shares a similar adverse effect profile with galantamine.
Drug and food interactions
darunavir food
Applies to: cobicistat / darunavir
Food can enhance the levels of darunavir in your body. Take darunavir with food. The type of food does not matter. This will make it easier for your body to absorb the medication. Swallow the whole tablets with a drink such as water or milk. Do not chew the tablets. Darunavir must be always be taken together at the same time as another medication called ritonavir (Norvir).
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Cabenuva
Cabenuva (cabotegravir and rilpivirine) injections are a long-acting HIV treatment used to keep HIV ...
Biktarvy
Biktarvy is a complete HIV-1 treatment in a once-a-day single tablet containing three antiviral ...
Botox
Botox is used to treat chronic migraines, excessive sweating, bladder conditions, eye muscle ...
Descovy
Descovy is used to treat and prevent HIV infection in adults and adolescents. When used for HIV-1 ...
Dovato
Dovato is used to treat HIV-1 infection in adults and children 12 years and older weighing at least ...
Truvada
Truvada is used to prevent HIV (HIV PrEP) or treat HIV-1 infection in combination with other HIV-1 ...
Atripla
Atripla prevents the human immunodeficiency virus (HIV) from reproducing in your body. Learn about ...
Isentress
Isentress is used to treat HIV, which causes acquired immunodeficiency syndrome (AIDS). Learn about ...
Viread
Viread (tenofovir) is used to treat HIV, which causes the acquired immunodeficiency syndrome ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.